Developer docs
API playgroundTry for free, no card

Search company profiles

Ilya Pharma

Full company profile

uuid0003523

Namestring
Ilya Pharma
Legal namestring
Ilya Pharma AB
Websiteurl
ilyapharma.se
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Ilya Pharma AB is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Uppsala, Sweden, that develops living biotherapeutic products (LBPs) based on engineered Limosilactobacillus reuteri. The platform programs the bacterium to act as a local mini-bioreactor at the disease site, secreting therapeutic human proteins. The lead asset, ILP100 (emilimogene sigulactibac), is a proprietary L. reuteri strain engineered to express human CXCL12, and is being developed in three formulations: ILP100-Topical (chronic and surgical wounds, with a lead SAVI indication under FDA Rare Pediatric Disease Designation), ILP100-Oral (ulcerative colitis and chemotherapy-induced or ICI-induced mucositis), and ILP101-Inhale (pulmonary infections, including antimicrobial-resistant indications). The platform is classified as a Gene Therapy Medicinal Product by both EMA and FDA, conferring specific regulatory pathways and the potential for a Priority Review Voucher upon approval of the lead asset.

The company operates a conventional clinical-stage biotech business model with no current product revenue: capital is raised through a mix of non-dilutive EU grants (Horizon 2020 SME Phase 2, EIC Accelerator including the WHILYAs-2 award) and private equity rounds, including an EUR 8.5M round in 2022 anchored by the EIC Fund and family offices, and a EUR 5M round in 2024. Total disclosed funding exceeds EUR 20M. The 2022 acquisition of Nordic Bioanalysis brought bioanalytical capabilities in-house, supporting clinical pharmacokinetic and CMC work. Partnerships with Uppsala University (co-founder Mia Phillipson), NIH, Great Ormond Street Hospital, and University of Pennsylvania support clinical execution. The company employs 11-50 people, has indicated preparation for a potential public market listing, and is led by a team that includes former Pfizer executive Sylvia McBrinn.

Revenue mechanics are pre-commercial: the company is funded to advance its pipeline through Phase 2/3 and to regulatory approval, with future monetization expected via direct commercialization in specialty indications, partnership/licensing deals, or potential Priority Review Voucher monetization. Customer segments in the eventual commercial setting are expected to be specialty wound care centers, gastroenterology practices, and pulmonary/critical care providers, though no products are yet sold.

Short descriptiontext

Ilya Pharma AB is a clinical-stage Swedish biopharmaceutical company developing engineered Limosilactobacillus reuteri living biotherapeutic products, with lead asset ILP100 delivering human CXCL12 for wound healing, oral mucositis, and pulmonary infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
living biotherapeutics development, gene therapy medicinal products, wound healing immunotherapy, engineered probiotic therapeutics, chemokine-based biologics
Industry5 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Immunotherapies
Social media profiles2 records
Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Ilya Pharma is a clinical-stage biopharma company developing novel immunotherapies. The company is developing multiple drug candidates (ILP100-Topical, ILP100-Oral, ILP101-Inhale) targeting rare diseases (SAVI, Cystic Fibrosis) and broader indications (ICI-induced colitis, diabetic wounds). Revenue would be generated through product sales upon regulatory approval.

ilyapharma.se
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ilya Pharma develops living biotherapeutic drug candidates using engineered Limosilactobacillus reuteri as local mini-bioreactors that produce human therapeutic chemokines (CXCL12, CXCL17) directly at disease sites. The lead asset ILP100 (emilimogene sigulactibac) is being developed in topical and oral formulations for wound healing, SAVI, and ICI-induced colitis, with ILP101-Inhale targeting MDR lung infections in Cystic Fibrosis and SAVI patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ILP100-Topical demonstrated 10 days faster skin healing in first-in-human double-blinded RCT
+3 more records
Product overview1 text field

Ilya Pharma is developing a portfolio of living biotherapeutic products based on its proprietary ILP-technology platform. The platform leverages engineered lactic acid bacteria (Limosilactobacillus reuteri) as local mini-bioreactors to produce human therapeutic proteins at the site of disease. The lead product is ILP100 (emilimogene sigulactibac), available in two formulations: ILP100-Topical for wound healing applications including SAVI and diabetic foot ulcers, and ILP100-Oral for ICI-induced colitis. Additional pipeline programs include ILP101-Inhale for respiratory diseases. The technology enables delivery of proteins unsuitable for traditional biologics, offering advantages including ambient temperature storage, favorable safety profile, and potential to address over 1700 proteins.

Product and service3 records
1ILP100-Topical (emilimogene sigulactibac)
CategoryLiving biotherapeutic - wound healing and rare disease
Description

Topical formulation of L. reuteri expressing human CXCL12 1a for treatment of difficult-to-heal skin wounds, including pediatric SAVI, diabetic foot ulcers, and surgical wounds in patients with prediabetes, diabetes, and obesity. A first-in-human double-blinded RCT demonstrated 10 days faster skin healing with a favorable safety profile. FDA RPDD with PRV eligibility granted for SAVI indication.

2ILP100-Oral (emilimogene sigulactibac)
CategoryLiving biotherapeutic - gastrointestinal disease
Description

Oral formulation of L. reuteri expressing human CXCL12 1a for treatment of immune checkpoint inhibitor (ICI)-induced colitis in cancer patients. Demonstrated superior efficacy versus Infliximab (Remicade) and Vedolizumab (Entyvio) in preclinical colitis models with very favorable safety profile. FDA pre-IND meeting completed supporting first-line evaluation in mild and moderate ICI-induced colitis.

3ILP101-Inhale
CategoryLiving biotherapeutic - respiratory and antimicrobial resistance
Description

Inhaled formulation of L. reuteri expressing human CXCL17, a mucosal chemokine with anti-inflammatory and bacteria-killing effects. Being developed for lung diseases including Cystic Fibrosis and SAVI with lung phenotype to preserve lung function and treat multi-drug resistant (MDR) bacterial infections. Currently in non-clinical proof-of-concept stage.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeOthersAnnounced on2026-01-01
Description

Proposed new auditor for the company as per AGM proposal. Will replace current auditor upon shareholder approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Lead site for planned confirmatory clinical trial in SAVI patients with skin ulcers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-01-01
Description

Ilya Pharma was one of the first companies to use bioprocess equipment at GE Healthcare's newly opened Testa Center in Uppsala for validation and scale-up of manufacturing process. Reduced risk and accelerated time to clinical trial.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term research collaboration. Professor Mia Phillipson from Uppsala University is co-founder. Company extends research collaboration with Uppsala University. Industrial PhD student program B-ACTIVE.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner in B-ACTIVE Marie Skłodowska-Curie program. Collaborates on chemokine immunobiology research and doctoral training.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator and partner in B-ACTIVE Marie Skłodowska-Curie program. European academic thought leader in life sciences.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial planned together with experts at interferonopathies at NIH for pediatric SAVI patients. Planning 'An Open Label Dose Escalation Exploratory Phase 2 Study to Evaluate Safety and Biological Effect of ILP100-Topical in Subjects with SAVI'.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical development collaborator. KOL engagement and lead sites for clinical trials.

9Nordic Bioanalysis
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic investment/acquisition of bioanalytical company to facilitate development of ILP pipeline. Acquiring one of its long-term partners to strengthen supply chain. Leo Groenewegen appointed as CEO.

ilyapharma.se
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lead site for planned confirmatory clinical trial in SAVI patients.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing engineered probiotic (E. coli Nissle and SYNB8802) therapeutics as living biotherapeutics for metabolic and inflammatory diseases. Closest direct peer to Ilya Pharma's engineered-bacteria platform, although Ilya differentiates via topical/oral/inhaled formulations and chemokine delivery.

TypeDirect peer
Description

Privately held UK-based biotech using engineered Salmonella and Lactobacillus platforms for oncology and inflammatory disease. Comparable as an engineered live-biotherapeutic developer pursuing immuno-oncology and immunomodulation, with a similar bacterial-delivery modality.

TypeDirect peer
Description

Clinical-stage developer of defined bacterial consortia (live biotherapeutics) for immuno-oncology and inflammatory diseases including colitis. Directly comparable as a live-biotherapeutic company with immune-modulation programs, though Vedanta uses defined consortia rather than engineered single-strain platforms.

TypeEmerging player
Description

French biotech developing engineered microbiome therapeutics using phage-based and bacterial platforms (Eligobiotics). Comparable as a next-generation engineered-microbiome player tackling chronic inflammatory and infectious diseases.

5Novome Biotechnologies
TypeEmerging player
Description

Engineered bacterial therapeutics company (formerly a Chroma Medicine subsidiary) developing genetically engineered gut bacteria for enteric hyperoxaluria and inflammatory disease. Comparable chassis-based engineered probiotic approach, focused on GI indications similar to ILP100-Oral.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing live biotherapeutics (Full-Spectrum Microbiota, SER-109) for inflammatory and infectious diseases. Directly comparable as a live-biotherapeutic developer with oral bacterial therapeutics in IBD-adjacent indications.

TypeBroad incumbent
Description

Large, diversified medical device and wound-care company selling skin substitutes, regenerative wound matrices and surgical instruments. Comparable as a wound-healing market incumbent where Ilya Pharma's ILP100-Topical would compete in diabetic foot ulcer and complex wound care.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company (Apligraf, Dermagraft, PuraPly) focused on advanced wound care and surgical biologics. Comparable as a wound-care incumbent that ILP100-Topical would compete against for diabetic foot ulcer and chronic wound market share.

TypeBroad incumbent
Description

Commercial-stage gene therapy company (Hemgenix for hemophilia B) with AAV-based GTMP experience and EMA/FDA regulatory expertise. Comparable as a GTMP-classified gene therapy developer navigating the same regulatory framework that governs Ilya Pharma's ILP platform.

TypeBroad incumbent
Description

Global pharmaceutical company marketing Entyvio (vedolizumab), the leading anti-α4β7 biologic for ulcerative colitis and Crohn's disease. Directly comparable as the benchmark incumbent whose drug ILP100-Oral demonstrated preclinical superiority over in colitis models.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ilya Pharma

Biopharmaceutical Immunotherapiesilyapharma.se

Ilya Pharma AB is a clinical-stage Swedish biopharmaceutical company developing engineered Limosilactobacillus reuteri living biotherapeutic products, with lead asset ILP100 delivering human CXCL12 for wound healing, oral mucositis, and pulmonary infections.

What Ilya Pharma does

Ilya Pharma AB is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Uppsala, Sweden, that develops living biotherapeutic products (LBPs) based on engineered Limosilactobacillus reuteri. The platform programs the bacterium to act as a local mini-bioreactor at the disease site, secreting therapeutic human proteins. The lead asset, ILP100 (emilimogene sigulactibac), is a proprietary L. reuteri strain engineered to express human CXCL12, and is being developed in three formulations: ILP100-Topical (chronic and surgical wounds, with a lead SAVI indication under FDA Rare Pediatric Disease Designation), ILP100-Oral (ulcerative colitis and chemotherapy-induced or ICI-induced mucositis), and ILP101-Inhale (pulmonary infections, including antimicrobial-resistant indications). The platform is classified as a Gene Therapy Medicinal Product by both EMA and FDA, conferring specific regulatory pathways and the potential for a Priority Review Voucher upon approval of the lead asset.

The company operates a conventional clinical-stage biotech business model with no current product revenue: capital is raised through a mix of non-dilutive EU grants (Horizon 2020 SME Phase 2, EIC Accelerator including the WHILYAs-2 award) and private equity rounds, including an EUR 8.5M round in 2022 anchored by the EIC Fund and family offices, and a EUR 5M round in 2024. Total disclosed funding exceeds EUR 20M. The 2022 acquisition of Nordic Bioanalysis brought bioanalytical capabilities in-house, supporting clinical pharmacokinetic and CMC work. Partnerships with Uppsala University (co-founder Mia Phillipson), NIH, Great Ormond Street Hospital, and University of Pennsylvania support clinical execution. The company employs 11-50 people, has indicated preparation for a potential public market listing, and is led by a team that includes former Pfizer executive Sylvia McBrinn.

Revenue mechanics are pre-commercial: the company is funded to advance its pipeline through Phase 2/3 and to regulatory approval, with future monetization expected via direct commercialization in specialty indications, partnership/licensing deals, or potential Priority Review Voucher monetization. Customer segments in the eventual commercial setting are expected to be specialty wound care centers, gastroenterology practices, and pulmonary/critical care providers, though no products are yet sold.

Ilya Pharma firmographics

Firmographics
Name
Ilya Pharma
Legal name
Ilya Pharma AB
Website
https://ilyapharma.se
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Ilya Pharma AB is a clinical-stage Swedish biopharmaceutical company developing engineered Limosilactobacillus reuteri living biotherapeutic products, with lead asset ILP100 delivering human CXCL12 for wound healing, oral mucositis, and pulmonary infections.
Ownership category
akta.pro rank

Ilya Pharma industry classification

Industry
Product category
Biopharmaceutical Immunotherapies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Living biotherapeutics development
  • Gene therapy medicinal products
  • Wound healing immunotherapy
  • Engineered probiotic therapeutics
  • Chemokine-based biologics

Where Ilya Pharma is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Ilya Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Ilya Pharma is a clinical-stage biopharma company developing novel immunotherapies. The company is developing multiple drug candidates (ILP100-Topical, ILP100-Oral, ILP101-Inhale) targeting rare diseases (SAVI, Cystic Fibrosis) and broader indications (ICI-induced colitis, diabetic wounds). Revenue would be generated through product sales upon regulatory approval.

Distribution channels1 record

Marketing channels5 records

Ilya Pharma product offering

Product offering

Core offering

Ilya Pharma develops living biotherapeutic drug candidates using engineered Limosilactobacillus reuteri as local mini-bioreactors that produce human therapeutic chemokines (CXCL12, CXCL17) directly at disease sites. The lead asset ILP100 (emilimogene sigulactibac) is being developed in topical and oral formulations for wound healing, SAVI, and ICI-induced colitis, with ILP101-Inhale targeting MDR lung infections in Cystic Fibrosis and SAVI patients.

Product overview

Ilya Pharma is developing a portfolio of living biotherapeutic products based on its proprietary ILP-technology platform. The platform leverages engineered lactic acid bacteria (Limosilactobacillus reuteri) as local mini-bioreactors to produce human therapeutic proteins at the site of disease. The lead product is ILP100 (emilimogene sigulactibac), available in two formulations: ILP100-Topical for wound healing applications including SAVI and diabetic foot ulcers, and ILP100-Oral for ICI-induced colitis. Additional pipeline programs include ILP101-Inhale for respiratory diseases. The technology enables delivery of proteins unsuitable for traditional biologics, offering advantages including ambient temperature storage, favorable safety profile, and potential to address over 1700 proteins.

Differentiator

Problem solved

Functional benefit

Products and services

  • ILP100-Topical (emilimogene sigulactibac) Topical formulation of L. reuteri expressing human CXCL12 1a for treatment of difficult-to-heal skin wounds, including pediatric SAVI, diabetic foot ulcers, and surgical wounds in patients with prediabetes, diabetes, and obesity. A first-in-human double-blinded RCT demonstrated 10 days faster skin healing with a favorable safety profile. FDA RPDD with PRV eligibility granted for SAVI indication.
  • ILP100-Oral (emilimogene sigulactibac) Oral formulation of L. reuteri expressing human CXCL12 1a for treatment of immune checkpoint inhibitor (ICI)-induced colitis in cancer patients. Demonstrated superior efficacy versus Infliximab (Remicade) and Vedolizumab (Entyvio) in preclinical colitis models with very favorable safety profile. FDA pre-IND meeting completed supporting first-line evaluation in mild and moderate ICI-induced colitis.
  • ILP101-Inhale Inhaled formulation of L. reuteri expressing human CXCL17, a mucosal chemokine with anti-inflammatory and bacteria-killing effects. Being developed for lung diseases including Cystic Fibrosis and SAVI with lung phenotype to preserve lung function and treat multi-drug resistant (MDR) bacterial infections. Currently in non-clinical proof-of-concept stage.

Quantifiable outcome

  • ILP100-Topical demonstrated 10 days faster skin healing in first-in-human double-blinded RCT
  • +3 more outcomes

Companies that use Ilya Pharma

Customer profile

Segments4 records

Ideal customer profiles3 records

Ilya Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ilya Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • KPMGminorOthers · 1 January 2026Proposed new auditor for the company as per AGM proposal. Will replace current auditor upon shareholder approval.
  • Great Ormond Street HospitalcoreStrategic or Co-development Partner · 1 January 2024Lead site for planned confirmatory clinical trial in SAVI patients with skin ulcers.
  • GE Healthcare Testa CentercoreTechnology or Integration · 1 January 2018Ilya Pharma was one of the first companies to use bioprocess equipment at GE Healthcare's newly opened Testa Center in Uppsala for validation and scale-up of manufacturing process. Reduced risk and accelerated time to clinical trial.
  • Uppsala UniversitycoreStrategic or Co-development PartnerLong-term research collaboration. Professor Mia Phillipson from Uppsala University is co-founder. Company extends research collaboration with Uppsala University. Industrial PhD student program B-ACTIVE.
  • Swedish University of Agricultural Sciences (SLU)coreStrategic or Co-development PartnerAcademic partner in B-ACTIVE Marie Skłodowska-Curie program. Collaborates on chemokine immunobiology research and doctoral training.
  • KU Leuven (Katholieke Universiteit Leuven)coreStrategic or Co-development PartnerAcademic collaborator and partner in B-ACTIVE Marie Skłodowska-Curie program. European academic thought leader in life sciences.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerClinical trial planned together with experts at interferonopathies at NIH for pediatric SAVI patients. Planning 'An Open Label Dose Escalation Exploratory Phase 2 Study to Evaluate Safety and Biological Effect of ILP100-Topical in Subjects with SAVI'.
  • Akademiska (Uppsala University Hospital)coreStrategic or Co-development PartnerClinical development collaborator. KOL engagement and lead sites for clinical trials.
  • Nordic BioanalysiscoreStrategic or Co-development PartnerStrategic investment/acquisition of bioanalytical company to facilitate development of ILP pipeline. Acquiring one of its long-term partners to strengthen supply chain. Leo Groenewegen appointed as CEO.
  • University of Pennsylvania (uPenn)coreStrategic or Co-development PartnerLead site for planned confirmatory clinical trial in SAVI patients.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

Ilya Pharma competitors and assessment

Company assessment

Direct peers

  • Synlogic: Clinical-stage company developing engineered probiotic (E. coli Nissle and SYNB8802) therapeutics as living biotherapeutics for metabolic and inflammatory diseases. Closest direct peer to Ilya Pharma's engineered-bacteria platform, although Ilya differentiates via topical/oral/inhaled formulations and chemokine delivery.
  • Prokarium: Privately held UK-based biotech using engineered Salmonella and Lactobacillus platforms for oncology and inflammatory disease. Comparable as an engineered live-biotherapeutic developer pursuing immuno-oncology and immunomodulation, with a similar bacterial-delivery modality.
  • Vedanta Biosciences: Clinical-stage developer of defined bacterial consortia (live biotherapeutics) for immuno-oncology and inflammatory diseases including colitis. Directly comparable as a live-biotherapeutic company with immune-modulation programs, though Vedanta uses defined consortia rather than engineered single-strain platforms.
  • Finch Therapeutics: Clinical-stage microbiome therapeutics company developing live biotherapeutics (Full-Spectrum Microbiota, SER-109) for inflammatory and infectious diseases. Directly comparable as a live-biotherapeutic developer with oral bacterial therapeutics in IBD-adjacent indications.

Emerging players

  • Eligo Bioscience: French biotech developing engineered microbiome therapeutics using phage-based and bacterial platforms (Eligobiotics). Comparable as a next-generation engineered-microbiome player tackling chronic inflammatory and infectious diseases.
  • Novome Biotechnologies: Engineered bacterial therapeutics company (formerly a Chroma Medicine subsidiary) developing genetically engineered gut bacteria for enteric hyperoxaluria and inflammatory disease. Comparable chassis-based engineered probiotic approach, focused on GI indications similar to ILP100-Oral.

Broad incumbents

  • Integra LifeSciences: Large, diversified medical device and wound-care company selling skin substitutes, regenerative wound matrices and surgical instruments. Comparable as a wound-healing market incumbent where Ilya Pharma's ILP100-Topical would compete in diabetic foot ulcer and complex wound care.
  • Organogenesis: Commercial-stage regenerative medicine company (Apligraf, Dermagraft, PuraPly) focused on advanced wound care and surgical biologics. Comparable as a wound-care incumbent that ILP100-Topical would compete against for diabetic foot ulcer and chronic wound market share.
  • uniQure: Commercial-stage gene therapy company (Hemgenix for hemophilia B) with AAV-based GTMP experience and EMA/FDA regulatory expertise. Comparable as a GTMP-classified gene therapy developer navigating the same regulatory framework that governs Ilya Pharma's ILP platform.
  • Takeda Pharmaceutical: Global pharmaceutical company marketing Entyvio (vedolizumab), the leading anti-α4β7 biologic for ulcerative colitis and Crohn's disease. Directly comparable as the benchmark incumbent whose drug ILP100-Oral demonstrated preclinical superiority over in colitis models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ilya Pharma social profiles

Digital presence

Ilya Pharma compliance and trust

Trust signal

Compliance4 records

Ilya Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ilya Pharma leadership team

Management profile

Number of profiles

Profiles9 records

Ilya Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Ilya Pharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ilya Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ilya Pharma

What does Ilya Pharma do?

Ilya Pharma develops living biotherapeutic drug candidates using engineered Limosilactobacillus reuteri as local mini-bioreactors that produce human therapeutic chemokines (CXCL12, CXCL17) directly at disease sites. The lead asset ILP100 (emilimogene sigulactibac) is being developed in topical and oral formulations for wound healing, SAVI, and ICI-induced colitis, with ILP101-Inhale targeting MDR lung infections in Cystic Fibrosis and SAVI patients.

Is Ilya Pharma a public or private company?

Ilya Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ilya Pharma founded?

Ilya Pharma was founded in 2016. It employs 11 to 50 people.

Where is Ilya Pharma based?

Ilya Pharma is headquartered in Uppsala, Sweden, in the Europe region.

How does Ilya Pharma make money?

One revenue line is on record: pharmaceutical product sales.

Who are Ilya Pharma's main competitors?

Direct peers on record are Synlogic, Prokarium, Vedanta Biosciences and Finch Therapeutics. Emerging players are Eligo Bioscience and Novome Biotechnologies. Broad incumbents are Integra LifeSciences, Organogenesis, uniQure and Takeda Pharmaceutical.

Does Ilya Pharma have an API?

No public API is recorded for Ilya Pharma.

What industry is Ilya Pharma in?

Ilya Pharma's product category is Biopharmaceutical Immunotherapies. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIlya Pharma announces FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesityIlya Pharma AB announced that the FDA has cleared an IND for its lead candidate ILP100-Topical, a first-in-class immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes, and obesity. The company is immediately accelerating preparations for a large adaptive Phase 2 study designed as a pivotal trial, which will include 260 patients and use an internal control design where each patient serves as their own control. The first patient is expected to be treated in Q3 2022.news.cision.comIlya Pharma strengthens board with appointments of corporate development specialist Hughes Crameri and Galderma veteran CarsonIlya Pharma appointed Melya Hughes Crameri and William Carson to its board of directors. The company is developing three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for diabetic wounds and ILP100-Oral for enterocolitis. CEO Evelina Vågesjö said the appointments strengthen the board's diversity and expertise.BioWorldIlya Pharma to trial advanced therapy to fix checkpoint inhibitor side effectsIlya Pharma AB will trial a novel cell therapy combining synthetic biology to address off-target side effects of checkpoint inhibitors. The therapy aims to focus the immune system on cancer, making treatment more tolerable and potentially improving survival rates.